From DCAT Value Chain Insights (VCI)
Takeda Pharmaceutical has partnered with Innovation Network Corporation of Japan (INCJ), a Tokyo-headquartered public-private partnership focused on promoting innovation and enhancing business value in Japan, and Medipal Holdings, a Tokyo-headquartered networking group of manufacturers, medical institutions, and retailers, to jointly invest a total of Japanese yen 10 billion ($87 million) to establish a new biotechnology venture company that will be named Scohia Pharma.
Following its launch within Takeda’s Shonan Research Center, Scohia Pharma will sign a license agreement with Takeda for eight of Takeda’s renal, metabolic, and cardiovascular research and development projects, with the goal of initiating operations on April 1, 2017.
Source Takeda Pharmaceutical
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription